Examining visceral leishmaniasis/HIV co-infection in East Africa

Download PDF Copy

Dec 9 2011

NewsGuard 100/100 Score

In this post in the Global Network for Neglected Tropical Diseases' (NTDs) "End the Neglect" blog, Julien Potet, NTD policy adviser at Medecins Sans Frontieres' Campaign for Access to Essential Medicines, examines the treatment of visceral leishmaniasis among people living with HIV in East Africa. He writes, "With new and better treatment strategies being validated, it is time for East African countries where visceral leishmaniasis is endemic -- mainly Sudan, South Sudan, Ethiopia and Kenya -- to scale up their capacities for integrated diagnosis and treatment of HIV and visceral leishmaniasis" (12/8).

This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News | Healthcare News

Tags: Health Care, HIV, HIV/AIDS, HIV-1, Leishmaniasis, Research, Tropical Disease

Comments (0)

Download PDF Copy

Suggested Reading

Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus

Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus

Study shows safety of kidney transplants among those with HIV infections

Study shows safety of kidney transplants among those with HIV infections

Iron supplements may boost brain development in children with HIV

Iron supplements may boost brain development in children with HIV

Georgetown University receives $27.5 million grant to combat HIV/AIDS in Haiti

Georgetown University receives $27.5 million grant to combat HIV/AIDS in Haiti

Affordability and supply remain critical to the success of long-lasting HIV drug

Affordability and supply remain critical to the success of long-lasting HIV drug

Study uncovers key mechanism behind HIV latency

Study uncovers key mechanism behind HIV latency

New two-dose HIV vaccine strategy shows promise for stronger immune response

New two-dose HIV vaccine strategy shows promise for stronger immune response

Exclusion of indigenous voices hinders HIV progress in Latin America

Exclusion of indigenous voices hinders HIV progress in Latin America

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New insights into the mechanisms of efavirenz-induced neurotoxicity